KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Share-based Compensation (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Share-based Compensation for 17 consecutive years, with $15.9 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 3.05% to $15.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $62.8 million through Dec 2025, down 2.03% year-over-year, with the annual reading at $58.0 million for FY2025, 6.9% down from the prior year.
  • Share-based Compensation for Q4 2025 was $15.9 million at Bio-Rad Laboratories, up from $14.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $18.1 million in Q4 2022, with the low at $11.4 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $14.8 million, with a median of $15.3 million recorded in 2021.
  • The sharpest move saw Share-based Compensation grew 29.55% in 2021, then fell 10.5% in 2023.
  • Over 5 years, Share-based Compensation stood at $15.0 million in 2021, then grew by 20.67% to $18.1 million in 2022, then dropped by 10.5% to $16.2 million in 2023, then increased by 1.23% to $16.4 million in 2024, then decreased by 3.05% to $15.9 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $15.9 million, $14.9 million, and $16.4 million for Q4 2025, Q3 2025, and Q4 2024 respectively.